UNSPSC 51171949: Pirenzepine

This classification denotes an antimuscarinic agent with the molecular formula C19H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G0285N20N, chemically known as 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one but generally known as pirenzepine, which bears US NIH Compound Identifier 4848. European Medicines Agency schedules Pirenzepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09904MIG.

UNSPSC 51171949 Pirenzepine (Commodity) appears in state and local procurement records tied to drug testing and pharmaceutical supply operations, though recent solicitations show limited direct demand for this specific pharmaceutical product. State and local governments soliciting under this code are primarily pursuing offender drug testing services, generic pharmaceutical distribution through cooperative purchasing vehicles, and exploratory direct-to-manufacturer pharmacy programs. The Commodity code nominally identifies a single pharmaceutical agent, but the recent opportunities indexed to it span broader specimen collection, laboratory testing, and multi-source drug supply contracting rather than procurement of pirenzepine itself.

The geographic footprint of recent activity centers on Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department (Texas) posted an RFP on July 9, 2026 for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals; the scope includes immunoassay screening with confirmatory testing via LC/MS/MS or GC/MS at two collection sites serving approximately 25,031 annual tests. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription programs for self-insured state employee health plans, a preliminary market-intelligence effort without binding timelines or award values. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and extending to participating Oregon jurisdictions; evaluation weights price competitiveness at 75 percent, with contracts effective July 1, 2026 for two years. The code shows fragmented activity across state corrections, state health programs, and cooperative purchasing networks rather than concentrated demand for pirenzepine specifically.